⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22186651 | 0.82 | — | — | |
| SCHEMBL3670583 | 0.80 | — | — | |
| SCHEMBL19890815 | 0.78 | HSD17B10 (0.43) | — | |
| SCHEMBL368639 | 0.78 | HSD17B10 (0.50) | — | |
| SCHEMBL3902717 | 0.76 | ALDH1A1 (0.40) | — | |
| SCHEMBL3910069 | 0.75 | ALDH1A1 (0.37) | — | |
| SCHEMBL15081830 | 0.74 | — | — | |
| SCHEMBL13800945 | 0.73 | HSD17B10 (0.40) | — | |
| SCHEMBL12205520 | 0.72 | — | — | |
| SCHEMBL18364468 | 0.72 | ALDH1A1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658072-A4 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2009-03-25 | — | — | EP | claimed |
| US-20070270426-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2007-11-22 | — | — | US | claimed |
| US-7253195-B2 | Compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-08-07 | — | — | US | claimed |
| EP-1658072-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| WO-2005020991-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050043372-A1 | Compounds for the treatment of neurodegenerative disorders | PFIZER, INC. (US) | 2005-02-24 | — | — | US | claimed |
| US-8815858-B2 | Heterocyclic flaviviridae virus inhibitors | GILEAD SCIENCES, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130171102-A1 | HETEROCYCLIC FLAVIVIRIDAE VIRUS INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| EP-1658072-A4 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080249094-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-10-09 | — | — | US | disclosed |
| US-7408068-B2 | Compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20070270426-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2007-11-22 | — | — | US | disclosed |
| US-7253195-B2 | Compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1658072-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005020991-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050043372-A1 | Compounds for the treatment of neurodegenerative disorders | PFIZER, INC. (US) | 2005-02-24 | — | — | US | disclosed |
| US-4593087-A | Disperse and acid azo dyes having one or two cinnamoyl substituents on a thiazole, isothiazole or thiadiazole diazonium moiety and having an aniline, tetrahydroquinoline or benzomorpholine coupler | EASTMAN KODAK COMPANY (US) | 1986-06-03 | — | — | US | disclosed |